Selected studies for predictors of radiological damage progression to MTX.
| Study Design | Reference | No. Patients | Treatment | Radiologic Score | Risk of Bias/Oxford Level |
|---|---|---|---|---|---|
| Prospective RCT in early active RA (except for TEMPO) | Smolen5, ASPIRE | 1004 total 298 MTX | MTX 20 mg; followup: 54 wks | Modified Sharp/Van der Heijde | Low/2b |
| Weinblatt8, TEMPO and ERA | 212 TEMPO (71 early RA subgroup) 213 ERA | MTX 20 mg; followup: 52 weeks | Total Sharp score | Moderate/2b | |
| Rau6 | 87 | MTX 15 mg; followup: 1 yr | Modified Larsen and Sharp | Low/2b | |
| Van der Heijde9, PREMIER | 187 | MTX 20 mg; followup: 1 yr | Total Sharp score | Moderate-high/4 (lack of information) |